[
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Was a Winner Today",
    "summary": "A news article implied that the company might have an advantage in the weight loss drug race.",
    "url": "https://finnhub.io/api/news?id=b3cddc5cada1b96c35e68d2247b85a445f4566fcb0e1d5a57f38bb2bdd3b7d7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758064523,
      "headline": "Why Eli Lilly Stock Was a Winner Today",
      "id": 136787475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A news article implied that the company might have an advantage in the weight loss drug race.",
      "url": "https://finnhub.io/api/news?id=b3cddc5cada1b96c35e68d2247b85a445f4566fcb0e1d5a57f38bb2bdd3b7d7c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses (6 mg, 12 mg and 36 mg) of orforglipron met the primary endpoint of superior body weight reduction compared to placebo. In addition, all three dose",
    "url": "https://finnhub.io/api/news?id=546c1aeb7a6a2928dc4fa07526e6e35a6de4e2c4b41ffa14252bc9d290988648",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758063660,
      "headline": "Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine",
      "id": 136787476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses (6 mg, 12 mg and 36 mg) of orforglipron met the primary endpoint of superior body weight reduction compared to placebo. In addition, all three dose",
      "url": "https://finnhub.io/api/news?id=546c1aeb7a6a2928dc4fa07526e6e35a6de4e2c4b41ffa14252bc9d290988648"
    }
  },
  {
    "ts": null,
    "headline": "Why the Market Dipped But Eli Lilly (LLY) Gained Today",
    "summary": "Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=01bbd0bac03f99158261b2a0e0b02b6d06865dc7dae13bc8e25a1f039386a508",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758062704,
      "headline": "Why the Market Dipped But Eli Lilly (LLY) Gained Today",
      "id": 136787477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=01bbd0bac03f99158261b2a0e0b02b6d06865dc7dae13bc8e25a1f039386a508"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: Hershey, Oracle, New York Times",
    "summary": "↗️Hershey (HSY): Shares in the chocolate maker rose 4.3% after Goldman Sachs upgraded its recommendation on the shares to buy from sell. ↘️ Hims & Hers (HIMS): Shares of the telehealth platform dropped 5.",
    "url": "https://finnhub.io/api/news?id=654e2c1c633b1bbb8438213657b73e74bbffa574a29e558e1ff849e90c9efbb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758057070,
      "headline": "Stocks to Watch Recap: Hershey, Oracle, New York Times",
      "id": 136787478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️Hershey (HSY): Shares in the chocolate maker rose 4.3% after Goldman Sachs upgraded its recommendation on the shares to buy from sell. ↘️ Hims & Hers (HIMS): Shares of the telehealth platform dropped 5.",
      "url": "https://finnhub.io/api/news?id=654e2c1c633b1bbb8438213657b73e74bbffa574a29e558e1ff849e90c9efbb2"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index adding 0.3% an",
    "url": "https://finnhub.io/api/news?id=d61bd41738d0865bd4bd859b7d62e736c49dd77d6620765e52e0591690fe6917",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758056411,
      "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
      "id": 136782146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index adding 0.3% an",
      "url": "https://finnhub.io/api/news?id=d61bd41738d0865bd4bd859b7d62e736c49dd77d6620765e52e0591690fe6917"
    }
  },
  {
    "ts": null,
    "headline": "Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat",
    "summary": "Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat",
    "url": "https://finnhub.io/api/news?id=4b91e38fc722bff1747acb1ffb644255c071c33cdf300df44bfaf6149f183735",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052800,
      "headline": "Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat",
      "id": 136867252,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat",
      "url": "https://finnhub.io/api/news?id=4b91e38fc722bff1747acb1ffb644255c071c33cdf300df44bfaf6149f183735"
    }
  },
  {
    "ts": null,
    "headline": "Citi Maintains a Buy Rating on Eli Lilly and Company (LLY), Retains the $1,190 PT",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy right now. Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) on September 10, retaining the price target of $1,190.00. The analyst supported the optimistic outlook with the promising outlook for the company’s obesity treatment, tirzepatide, stating […]",
    "url": "https://finnhub.io/api/news?id=6a8e52d1461cafbbf674cdf63fcec9fae6909add0d826abfd6f142cf5a06047d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052687,
      "headline": "Citi Maintains a Buy Rating on Eli Lilly and Company (LLY), Retains the $1,190 PT",
      "id": 136782147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy right now. Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) on September 10, retaining the price target of $1,190.00. The analyst supported the optimistic outlook with the promising outlook for the company’s obesity treatment, tirzepatide, stating […]",
      "url": "https://finnhub.io/api/news?id=6a8e52d1461cafbbf674cdf63fcec9fae6909add0d826abfd6f142cf5a06047d"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on Value investing subreddit by Remarkable-Ad5326. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $25.27 as of September 9th. Viking Therapeutics (VKTX), a $3 billion pharma company, is emerging as one of the most mispriced stocks in […]",
    "url": "https://finnhub.io/api/news?id=0918848bb286ac7d12014d9e4a36ead287c7aad2fc8f1658e41f1a13a4da1e3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758049454,
      "headline": "Viking Therapeutics, Inc. (VKTX): A Bull Case Theory",
      "id": 136781278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Viking Therapeutics, Inc. on Value investing subreddit by Remarkable-Ad5326. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $25.27 as of September 9th. Viking Therapeutics (VKTX), a $3 billion pharma company, is emerging as one of the most mispriced stocks in […]",
      "url": "https://finnhub.io/api/news?id=0918848bb286ac7d12014d9e4a36ead287c7aad2fc8f1658e41f1a13a4da1e3c"
    }
  },
  {
    "ts": null,
    "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
    "summary": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
    "url": "https://finnhub.io/api/news?id=a9cc0127fb52e5bad111cbe0fae4993c98de24e14a4e6477842edd38fbb9d840",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758049260,
      "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
      "id": 136803527,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
      "url": "https://finnhub.io/api/news?id=a9cc0127fb52e5bad111cbe0fae4993c98de24e14a4e6477842edd38fbb9d840"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Tuesday Afternoon",
    "summary": "Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index adding 0.4% and the H",
    "url": "https://finnhub.io/api/news?id=4e4351ac98371d9be853ea5badd5937ed3b12de95009219357b376e6383840b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758048641,
      "headline": "Sector Update: Health Care Stocks Rise Tuesday Afternoon",
      "id": 136781279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index adding 0.4% and the H",
      "url": "https://finnhub.io/api/news?id=4e4351ac98371d9be853ea5badd5937ed3b12de95009219357b376e6383840b0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to invest $5B on Virginia plant amid Trump's pharma tariff threats",
    "summary": "Pharmaceutical giant Eli Lilly expanded its Virginia facility investment plans to $5 billion from original $2.1 billion amid the Trump administration tariff threats on drug imports.",
    "url": "https://finnhub.io/api/news?id=3e3419649a9f808f2973ddf9b0366d4a354df2b7e7f25acb2aa7107e716d7ec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758048060,
      "headline": "Eli Lilly to invest $5B on Virginia plant amid Trump's pharma tariff threats",
      "id": 136782148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical giant Eli Lilly expanded its Virginia facility investment plans to $5 billion from original $2.1 billion amid the Trump administration tariff threats on drug imports.",
      "url": "https://finnhub.io/api/news?id=3e3419649a9f808f2973ddf9b0366d4a354df2b7e7f25acb2aa7107e716d7ec3"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Reiterates Eli Lilly (LLY) Buy on GLP-1 Growth Momentum",
    "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best ESG stocks to buy now according to hedge funds. On September 9, Bank of America’s Tim Anderson reiterated a Buy rating on Eli Lilly & Co. (NYSE:LLY) and a $900 price target. The analyst highlighted the company’s strong market position in the obesity drug market as […]",
    "url": "https://finnhub.io/api/news?id=ad9c752474847bcbe35a6d1147c7c358ed4b281b9a08026a82e04554afe99393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758047663,
      "headline": "Bank of America Reiterates Eli Lilly (LLY) Buy on GLP-1 Growth Momentum",
      "id": 136781280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best ESG stocks to buy now according to hedge funds. On September 9, Bank of America’s Tim Anderson reiterated a Buy rating on Eli Lilly & Co. (NYSE:LLY) and a $900 price target. The analyst highlighted the company’s strong market position in the obesity drug market as […]",
      "url": "https://finnhub.io/api/news?id=ad9c752474847bcbe35a6d1147c7c358ed4b281b9a08026a82e04554afe99393"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly plans to build a $5 billion drug making plant in Goochland County: What we know",
    "summary": "Eli Lilly & Co. plans to create 650 'high-paying' jobs at its first Virginia facility, plus another 1,800 jobs in construction to build it.",
    "url": "https://finnhub.io/api/news?id=c9f181401de5a6f9c2b97e6adf42d382fde5cd68ca5db3542efd710c7a33caa7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758047200,
      "headline": "Eli Lilly plans to build a $5 billion drug making plant in Goochland County: What we know",
      "id": 136781281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Co. plans to create 650 'high-paying' jobs at its first Virginia facility, plus another 1,800 jobs in construction to build it.",
      "url": "https://finnhub.io/api/news?id=c9f181401de5a6f9c2b97e6adf42d382fde5cd68ca5db3542efd710c7a33caa7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Invest $5 Billion to Build First of 4 Planned Manufacturing Sites in US",
    "summary": "Eli Lilly (LLY) said Tuesday it intends to invest $5 billion to construct a manufacturing facility i",
    "url": "https://finnhub.io/api/news?id=9d7e0b2fa1ef31b9c8dedbe088aef524c5d1dbee8991740f07aab1ea58268e99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758046730,
      "headline": "Eli Lilly to Invest $5 Billion to Build First of 4 Planned Manufacturing Sites in US",
      "id": 136781282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Tuesday it intends to invest $5 billion to construct a manufacturing facility i",
      "url": "https://finnhub.io/api/news?id=9d7e0b2fa1ef31b9c8dedbe088aef524c5d1dbee8991740f07aab1ea58268e99"
    }
  },
  {
    "ts": null,
    "headline": "AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?",
    "summary": "Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.",
    "url": "https://finnhub.io/api/news?id=7e39da9f066d83f8e6daf48c8f035e6212c064baab937ce0e5eb989930638999",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758045480,
      "headline": "AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?",
      "id": 136781283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.",
      "url": "https://finnhub.io/api/news?id=7e39da9f066d83f8e6daf48c8f035e6212c064baab937ce0e5eb989930638999"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Needs a Better Obesity Pipeline. Its Newest Data Looks Ho-Hum.",
    "summary": "The weight loss drugmaker Novo Nordisk is trying to shore up its obesity pipeline with a potential alternative to its blockbuster Wegovy.",
    "url": "https://finnhub.io/api/news?id=87a9e924d0179cb63f1f243443171281c1096a85d1edf07097df75cc68a5e8e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758042840,
      "headline": "Novo Nordisk Needs a Better Obesity Pipeline. Its Newest Data Looks Ho-Hum.",
      "id": 136773219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The weight loss drugmaker Novo Nordisk is trying to shore up its obesity pipeline with a potential alternative to its blockbuster Wegovy.",
      "url": "https://finnhub.io/api/news?id=87a9e924d0179cb63f1f243443171281c1096a85d1edf07097df75cc68a5e8e3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's $5B investment, Nvidia & China, Tesla safety probe",
    "summary": "Market Catalysts Host Julie Hyman and Senior Reporter Brooke DiPalma discuss some of the day's trending tickers, including Eli Lilly (LLY), Tesla (TSLA), and Nvidia (NVDA). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=3bcd19fd320480f4f5e1bdcbeb0b3fe3d54c3ccf6c0005090ceba69a5bc5083b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758041030,
      "headline": "Eli Lilly's $5B investment, Nvidia & China, Tesla safety probe",
      "id": 136773038,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market Catalysts Host Julie Hyman and Senior Reporter Brooke DiPalma discuss some of the day's trending tickers, including Eli Lilly (LLY), Tesla (TSLA), and Nvidia (NVDA). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=3bcd19fd320480f4f5e1bdcbeb0b3fe3d54c3ccf6c0005090ceba69a5bc5083b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Invest $5 Billion in New Virginia Drug Manufacturing Plant",
    "summary": "Plan is part of the drugmaker’s pledge to bolster its domestic medicine production with four new pharmaceutical manufacturing sites.",
    "url": "https://finnhub.io/api/news?id=0f110ef8400b11a6bf06844d7d637925d185d499362265bbb17bd955e6c809d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758038700,
      "headline": "Eli Lilly to Invest $5 Billion in New Virginia Drug Manufacturing Plant",
      "id": 136773221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Plan is part of the drugmaker’s pledge to bolster its domestic medicine production with four new pharmaceutical manufacturing sites.",
      "url": "https://finnhub.io/api/news?id=0f110ef8400b11a6bf06844d7d637925d185d499362265bbb17bd955e6c809d7"
    }
  },
  {
    "ts": null,
    "headline": "Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?",
    "summary": "AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.",
    "url": "https://finnhub.io/api/news?id=00a8d4a15be08a625d7c1fccc39ccddfca8ab52f3d09047edb68cea629a8bb57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758037860,
      "headline": "Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?",
      "id": 136773222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.",
      "url": "https://finnhub.io/api/news?id=00a8d4a15be08a625d7c1fccc39ccddfca8ab52f3d09047edb68cea629a8bb57"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: Eli Lilly's Weight-Loss Pill May Get FDA Approval by Year-End",
    "summary": "(Updates with FDA response in the fourth and fifth paragraphs.) Eli Lilly's (LLY) investigational",
    "url": "https://finnhub.io/api/news?id=b965502588ba6afc1db26f188c3dc1324085c37678c782abbbc21816f23752c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758037791,
      "headline": "Update: Market Chatter: Eli Lilly's Weight-Loss Pill May Get FDA Approval by Year-End",
      "id": 136773223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with FDA response in the fourth and fifth paragraphs.) Eli Lilly's (LLY) investigational",
      "url": "https://finnhub.io/api/news?id=b965502588ba6afc1db26f188c3dc1324085c37678c782abbbc21816f23752c4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to invest $5 billion in new Virginia plant as pharma braces for tariffs",
    "summary": "Eli Lilly said on Tuesday it will invest $5 billion to build a manufacturing facility in Virginia, part of the drugmaker's broader $27 billion plan to build four facilities across the United States over the next five years.  The investment marks Lilly's latest push to boost domestic drug production and hedge against potential tariffs.  Global pharmaceutical companies have been increasing U.S. investment to bolster manufacturing capacity after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.",
    "url": "https://finnhub.io/api/news?id=601c46616dc0933137cafffc2ef85654847ce1909acc4ace1def1a14f6473497",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758036802,
      "headline": "Eli Lilly to invest $5 billion in new Virginia plant as pharma braces for tariffs",
      "id": 136773224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said on Tuesday it will invest $5 billion to build a manufacturing facility in Virginia, part of the drugmaker's broader $27 billion plan to build four facilities across the United States over the next five years.  The investment marks Lilly's latest push to boost domestic drug production and hedge against potential tariffs.  Global pharmaceutical companies have been increasing U.S. investment to bolster manufacturing capacity after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.",
      "url": "https://finnhub.io/api/news?id=601c46616dc0933137cafffc2ef85654847ce1909acc4ace1def1a14f6473497"
    }
  },
  {
    "ts": null,
    "headline": "Lilly announces plans to build $5 billion manufacturing facility in Virginia",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company's first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio.",
    "url": "https://finnhub.io/api/news?id=2b1ded13e99f3de18d836d149070beea1b50c053de6128bb51ee70aea6bd9a60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758036600,
      "headline": "Lilly announces plans to build $5 billion manufacturing facility in Virginia",
      "id": 136773225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company's first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio.",
      "url": "https://finnhub.io/api/news?id=2b1ded13e99f3de18d836d149070beea1b50c053de6128bb51ee70aea6bd9a60"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY)’s Pharmaceutical Leadership as a Driver of Consistent Dividends",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an Indiana-based multinational pharmaceutical company. Analysts expect the company to remain a leader in the rapidly expanding weight-loss market at least through the end of the decade. Its drug tirzepatide, marketed as […]",
    "url": "https://finnhub.io/api/news?id=ce679dfbc05ec1c6391b90f7d7d2230abdb7bdf5698c89a5909c1e3c69f5306a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758036305,
      "headline": "Eli Lilly (LLY)’s Pharmaceutical Leadership as a Driver of Consistent Dividends",
      "id": 136773226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an Indiana-based multinational pharmaceutical company. Analysts expect the company to remain a leader in the rapidly expanding weight-loss market at least through the end of the decade. Its drug tirzepatide, marketed as […]",
      "url": "https://finnhub.io/api/news?id=ce679dfbc05ec1c6391b90f7d7d2230abdb7bdf5698c89a5909c1e3c69f5306a"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: Oracle, New York Times, Webtoon",
    "summary": "↗️ Oracle (ORCL): The tech giant co-founded by Republican megadonor Larry Ellison is expected to be involved in the deal to preserve TikTok’s access to the U.S. Shares rose more than 3% early Tuesday.",
    "url": "https://finnhub.io/api/news?id=69a6737101c2c5cf5825006d428212dfb14fb8988c9e0061ac92bf4d2cc3cd32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758035291,
      "headline": "Stocks to Watch Tuesday: Oracle, New York Times, Webtoon",
      "id": 136773163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Oracle (ORCL): The tech giant co-founded by Republican megadonor Larry Ellison is expected to be involved in the deal to preserve TikTok’s access to the U.S. Shares rose more than 3% early Tuesday.",
      "url": "https://finnhub.io/api/news?id=69a6737101c2c5cf5825006d428212dfb14fb8988c9e0061ac92bf4d2cc3cd32"
    }
  },
  {
    "ts": null,
    "headline": "Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?",
    "summary": "Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.",
    "url": "https://finnhub.io/api/news?id=4c41a5c461a2519788ce230712e9ac8751eb2f61259a4e6ddd06d2ed1b795638",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758030840,
      "headline": "Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?",
      "id": 136773228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.",
      "url": "https://finnhub.io/api/news?id=4c41a5c461a2519788ce230712e9ac8751eb2f61259a4e6ddd06d2ed1b795638"
    }
  },
  {
    "ts": null,
    "headline": "Drug developer Dualitas launches $65 million funding round",
    "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
    "url": "https://finnhub.io/api/news?id=881acb8e3ec0da75c8685720d14818e1f016a46b756a1e6e7dcec442db9db8dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024232,
      "headline": "Drug developer Dualitas launches $65 million funding round",
      "id": 136773229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
      "url": "https://finnhub.io/api/news?id=881acb8e3ec0da75c8685720d14818e1f016a46b756a1e6e7dcec442db9db8dd"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Wegovy may quiet thoughts about food, study shows; shares up",
    "summary": "Investing.com -- New research shows Novo Nordisk’s weight-loss drug Wegovy can help patients reduce constant thoughts about food, a finding that could broaden the drug’s appeal beyond weight management.",
    "url": "https://finnhub.io/api/news?id=e5fb27beda2e34145fbade4be2e53971717b47cb88463ea727c3211724215d65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024087,
      "headline": "Novo Nordisk’s Wegovy may quiet thoughts about food, study shows; shares up",
      "id": 136773230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- New research shows Novo Nordisk’s weight-loss drug Wegovy can help patients reduce constant thoughts about food, a finding that could broaden the drug’s appeal beyond weight management.",
      "url": "https://finnhub.io/api/news?id=e5fb27beda2e34145fbade4be2e53971717b47cb88463ea727c3211724215d65"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Discusses Novo Nordisk A/S (NVO) And CVS",
    "summary": "We recently published 8 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) revealed last week that it would cut 9,000 jobs as part of a cost-cutting push through which it expects to save $1.3 billion. The push comes at a time […]",
    "url": "https://finnhub.io/api/news?id=fe3935fa056a40b0a94cd290464bb3532d31f50e4afe3a71fdf76b842e864b3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758022057,
      "headline": "Jim Cramer Discusses Novo Nordisk A/S (NVO) And CVS",
      "id": 136773231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 8 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) revealed last week that it would cut 9,000 jobs as part of a cost-cutting push through which it expects to save $1.3 billion. The push comes at a time […]",
      "url": "https://finnhub.io/api/news?id=fe3935fa056a40b0a94cd290464bb3532d31f50e4afe3a71fdf76b842e864b3b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly weight-loss pill could be FDA-approved by year-end",
    "summary": "(Reuters) -Eli Lilly's experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.  Analysts speculate that the drug, orforglipron, is a viable candidate given the growing cost burden of expensive injectable weight-loss drugs and the fact that Lilly is expanding its U.S. manufacturing - issues the Trump Administration has prioritized.  Lilly, based in Indianapolis, declined to comment.",
    "url": "https://finnhub.io/api/news?id=477ef6bbb0316c20173192f4687324b07f27a1c5e7edb54ca5716f66ba1f559a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758020967,
      "headline": "Lilly weight-loss pill could be FDA-approved by year-end",
      "id": 136773232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Eli Lilly's experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.  Analysts speculate that the drug, orforglipron, is a viable candidate given the growing cost burden of expensive injectable weight-loss drugs and the fact that Lilly is expanding its U.S. manufacturing - issues the Trump Administration has prioritized.  Lilly, based in Indianapolis, declined to comment.",
      "url": "https://finnhub.io/api/news?id=477ef6bbb0316c20173192f4687324b07f27a1c5e7edb54ca5716f66ba1f559a"
    }
  },
  {
    "ts": null,
    "headline": "Here Is My Top Stock Pick Among the Weight Loss Industry Leaders",
    "summary": "The weight loss drug market may reach $95 billion within five years.",
    "url": "https://finnhub.io/api/news?id=b55381e2e6bf2a619aa46ce3cd34ec995d5a8e483b8a5faac0a5858fdf800f22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758010500,
      "headline": "Here Is My Top Stock Pick Among the Weight Loss Industry Leaders",
      "id": 136773233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The weight loss drug market may reach $95 billion within five years.",
      "url": "https://finnhub.io/api/news?id=b55381e2e6bf2a619aa46ce3cd34ec995d5a8e483b8a5faac0a5858fdf800f22"
    }
  }
]